胜搏发线上平台

<address id="hl1rz"></address>
<sub id="hl1rz"></sub>
<output id="hl1rz"><button id="hl1rz"></button></output>
  • <sub id="hl1rz"></sub><sub id="hl1rz"></sub>

                <sub id="hl1rz"></sub>
                <sub id="hl1rz"></sub>
                Guangming Online> World

                Therapeutic trial results against COVID-19 expected in 3 weeks: WHO chief

                SWITZERLAND-GENEVA-WHO-NCP-THERAPEUTIC TRIAL RESULTS

                The World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus (L) attends a daily briefing in Geneva, Switzerland, Feb. 20, 2020. WHO said Thursday that preliminary results from clinical trials of therapeutics against COVID-19 are expected in three weeks. (Xinhua/Chen Junxia)

                GENEVA, Feb. 21 (Xinhua) -- The World Health Organization (WHO) said Thursday that preliminary results from clinical trials of therapeutics against COVID-19 are expected in three weeks.

                "We're also looking forward to results from two clinical trials of therapeutics prioritized by the WHO R&D Blueprint," WHO Director-General Tedros Adhanom Ghebreyesus said at a daily briefing.

                One of the trials he referred to is the combination of two drugs for HIV, lopinavir and ritonavir, while the other is testing an antiviral called remdesivir. "We expect preliminary results in three weeks," he added.

                Remdesivir is a drug developed by U.S. pharmaceutical company Gilead Sciences. It has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments.

                It has also shown fairly good antiviral activity against the COVID-19 at the cellular level. A randomized, double-blind, placebo-controlled clinical trial of remdesivir started on Feb. 6 in several hospitals in the central Chinese city of Wuhan, and the trial will last until the end of April.

                A study published in 2004 showed the anti-HIV drug combination of Lopinavir and Ritonavir has "substantial clinical benefit" when given to patients who had SARS. The Wuhan Jinyintan Hospital, where the first 41 known patients were treated, has already launched a randomized, controlled trial of the anti-HIV drug combination, according to a report by Chinese researchers in the Lancet medical journal late last month.

                The third version of COVID-19 treatment guidelines published by China's National Health Commission suggested that taking two Lopinavir/Ritonavir pills and inhaling a dose of nebulized alpha-interferon twice a day could benefit patients.

                [ Editor: SRQ ]

                <address id="hl1rz"></address>
                <sub id="hl1rz"></sub>
                <output id="hl1rz"><button id="hl1rz"></button></output>
              1. <sub id="hl1rz"></sub><sub id="hl1rz"></sub>

                            <sub id="hl1rz"></sub>
                            <sub id="hl1rz"></sub>

                            博冠的彩的正确网址

                            盛皇彩票

                            万和城官网

                            百万发彩票登录-首页

                            彩客彩票网官方端口

                            bbin娱乐官网

                            金沙网上娱乐澳门

                            306.com彩票账号注册

                            梦之城|登录

                             

                            博冠的彩的正确网址

                            盛皇彩票

                            万和城官网

                            百万发彩票登录-首页

                            彩客彩票网官方端口

                            bbin娱乐官网

                            金沙网上娱乐澳门

                            306.com彩票账号注册

                            梦之城|登录